Skip to content

Migraine Prophylaxis With Clopidogrel Trial

A Prospective Trial to Evaluate the Effectiveness of Clopidogrel to Relieve Migraine With Right-to-left Shunt

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02938182
Enrollment
50
Registered
2016-10-19
Start date
2016-10-31
Completion date
2023-10-31
Last updated
2021-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Brief summary

The underlying mechanisms of association between the right-to-left shunts (RLS) and migraine may concern with platelet aggregation and paradoxical embolization. The aim of the study is to evaluate the prophylactic effectiveness of clopidogrel for migraineurs with RLS.

Detailed description

Many studies have shown an increased prevalence of right-to-left shunts in migraineurs. The underlying mechanisms of association between the right-to-left shunts (RLS) and migraine may concern with platelet aggregation and paradoxical embolization. In the present study, migraineurs without taking prophylactic medicines regularly will be given only clopidogrel 75 mg daily for three months. Migraineurs who are unresponsive to at least two commonly applied preventive medications, clopidogrel 75 mg daily will be added to his/her existing prophylactic migraine regimen for three months. Patients will be followed up at the third month and the sixth month for headache frequency, attack duration of headache, migraine disability assessment scale(MIDAS)scores, headache impact test(HIT-6)scores and visual analogue scale(VAS)scores. Investigators will evaluate the changes of these measurements between baseline and the follow-up time. The aim of the study is to evaluate the prophylactic effectiveness of clopidogrel for migraineurs with RLS.

Interventions

DRUGclopidogrel

clopidogrel troche 75 mg daily for three months

Sponsors

First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* migraine with or without aura diagnosed by a neurologist according to the criteria of the International Headache Society (3nd edition) * experience a minimum of two migraine attacks per month in a 3-month baseline phase * without regular use of prophylactic treatments or unresponsive to two and more commonly applied preventive medications * the presence of RLS confirmed by contrast-enhanced transcranial Doppler * no positive findings in cranial CT and MRI

Exclusion criteria

* other types of headaches * systemic chronic diseases, cerebrovascular disease, abnormal platelet or liver function * history of head injury * other contraindications to clopidogrel treatment

Design outcomes

Primary

MeasureTime frame
Change from Baseline Attack Duration of Headache at three months, hthree months

Secondary

MeasureTime frame
Change from Baseline Headache Frequency per Month at three months, timethree months
Change from Baseline Visual Analogue Scale at three months, scoresthree months
Change from Baseline Migraine Disability Assessment Scale at three months, scoresthree months
Change from Baseline Headache Impact Test at three months, scoresthree months

Countries

China

Contacts

Primary ContactGuogang Luo, doctor
lguogang@163.com0086-13991974085
Backup ContactDan Zhu, master
767441726@qq.com0086-15229233307

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026